NLR/PLR在原发性肝癌中的研究进展
Progress of Neutrophil to Lymphocyte Ratio/Platelet to Lymphocyte Ratio in Primary Liver Cancer
摘要: 肝癌是消化系统最常见的恶性肿瘤之一。肺癌、肝癌、胃癌、乳腺癌和结肠癌是癌症相关死亡的前五大主要原因，其中肝癌从2018年的第三高癌症死亡率上升到2020年的第二高。越来越多的证据表明全身炎症反应与癌症患者的预后有密切的关系，并且血清学的检查，相比于其他的检测手段来说更加简便、花费更小，因此血清炎症因子也得到了人们的广泛关注，其中最具代表性的是中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio, NLR)和血小板与淋巴细胞比值(platelet to lym-phocyte ratio, PLR)。NLR和PLR与肝癌的相关性研究已在各个阶段展开，全文就其在肝癌治疗预后中的临床作用进行综述。
Abstract: Liver cancer is one of the most common malignant tumors of digestive system. Lung, liver, stomach, breast and colon cancers are the top five leading causes of cancer-related deaths, with liver cancer rising from the third highest cancer death rate in 2018 to the second highest in 2020. More and more evidence shows that systemic inflammatory response is closely related to the prognosis of cancer patients, and serological tests are more convenient and less costly than other detection methods, so serum inflammatory factors have attracted wide attention, among which the most rep-resentative ones are neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). Studies on the correlation between NLR and PLR and liver cancer have been carried out at various stages. This paper reviews the clinical effects of NLR and PLR in the treatment and prognosis of liver cancer.
文章引用：史雨涵, 杨建军. NLR/PLR在原发性肝癌中的研究进展[J]. 临床医学进展, 2023, 13(8): 12552-12558. https://doi.org/10.12677/ACM.2023.1381761

参考文献

[1] Cao, W., Chen, H.-D., Yu, Y.-W., Li, N. and Chen, W.-Q. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791. [Google Scholar] [CrossRef] 
[2] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13.
[3] Coussens, L. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. [Google Scholar] [CrossRef] [PubMed]
[4] Yang, Y.M., Kim, S.Y. and Seki, E. (2019) Inflammation and Liver Can-cer: Molecular Mechanisms and Therapeutic Targets. Seminars in Liver Disease, 39, 26-42. [Google Scholar] [CrossRef] [PubMed]
[5] Llovet, J.M., Pinyol, R., Kelley, R.K., El-Khoueiry, A., Reeves, H.L., Wang, X.W., Gores, G.J. and Villanueva, A. (2022) Molecular Pathogenesis and Systemic Therapies for Hepatocellular Carcinoma. Nature Cancer, 3, 386-401. [Google Scholar] [CrossRef] [PubMed]
[6] Diakos, C.I., Charles, K.A., McMillan, D.C. and Clarke, S.J. (2014) Cancer-Related Inflammation and Treatment Effectiveness. The Lancet Oncology, 15, e493-e503. [Google Scholar] [CrossRef] 
[7] Coffelt, S.B., Wellenstein, M.D. and de Visser, K.E. (2016) Neutrophils in Cancer: Neutral no More. Nature Reviews Cancer, 16, 431-446. [Google Scholar] [CrossRef] [PubMed]
[8] Khandia, R. and Munjal, A. (2019) Interplay between Inflammation and Cancer. In: Donev, R., Ed., Advances in Protein Chemistry and Structural Biology, Vol. 119, Elsevier, Amsterdam, 199-245. [Google Scholar] [CrossRef] [PubMed]
[9] Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., et al. (2009) Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell, 16, 183-194. [Google Scholar] [CrossRef] [PubMed]
[10] Rawat, K., Syeda, S. and Shrivastava, A. (2021) Neutrophil-Derived Granule Cargoes: Paving the Way for Tumor Growth and Progression. Cancer and Metastasis Reviews, 40, 221-244. [Google Scholar] [CrossRef] [PubMed]
[11] Gooden, M.J., de Bock, G.H., Leffers, N., Daemen, T. and Nijman, H.W. (2011) The Prognostic Influence of Tumour-Infiltrating Lymphocytes in Cancer: A Systematic Review with Meta-Analysis. British Journal of Cancer, 105, 93-103. [Google Scholar] [CrossRef] [PubMed]
[12] 白素杭, 杨晓悦, 张楠, 张富涵, 沈宗毅, 杨娜, 张文赛, 喻长远, 杨昭. 肿瘤浸润淋巴细胞在实体肿瘤中作用的研究进展[J]. 生物工程学报,2019, 35(12): 2308-2325. [Google Scholar] [CrossRef] [PubMed]
[13] Schlesinger, M. (2018) Role of Platelets and Platelet Receptors in Cancer Metastasis. Journal of Hematology & Oncology, 11, Article No. 125. [Google Scholar] [CrossRef] [PubMed]
[14] 张呈, 马丽萍. 血小板与炎症-血栓网络[J]. 血栓与止血学, 2008, 14(3): 136-138.
[15] Iyengar, N.M., Gucalp, A., Dannenberg, A.J. and Hudis, C.A. (2016) Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. Journal of Clinical Oncology, 34, 4270-4276. [Google Scholar] [CrossRef] 
[16] 刘克颜, 宁召臣. 血小板在肿瘤转移中的作用[J]. 中国生物化学与分子生物学报, 2022, 38(8): 1006-1014. [Google Scholar] [CrossRef] 
[17] 周雷, 丁胜义, 雷响, 胡孔旺, 胡孔旺. 原发性肝细胞肝癌手术切除后复发的危险因素研究[J]. 肝胆外科杂志, 2021, 29(5): 369-372.
[18] Kim, W.-J., Lim, T.-W., Park, P.-J., Choi, S.-B. and Kim, W.-B. (2019) Prognostic Markers Affecting the Early Recurrence of Hepatocellular Carcino-ma with Liver Cirrhosis after Curative Resection. The International Journal of Biological Markers, 34, 123-131. [Google Scholar] [CrossRef] [PubMed]
[19] Kabir, T., Ye, M., Mohd Noor, N.A., Woon, W., Junnarkar, S.P. and Shelat, V.G. (2019) Preoperative Neutrophil-to-Lymphocyte Ratio plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma. International Journal of Hepatology, 2019, Article ID: 4239463. [Google Scholar] [CrossRef] [PubMed]
[20] 朱广志, 严律南, 彭涛. 中国《原发性肝癌诊疗指南(2022年版)》与《BCLC预后预测和治疗推荐策略(2022年版)》的解读[J]. 中国普外基础与临床杂志, 2022, 29(4): 434-439.
[21] Fu, H., Zheng, J., Cai, J., Zeng, K., Yao, J., Chen, L., et al. (2018) Systemic Immune-Inflammation In-dex (SII) Is Useful to Predict Survival Outcomes in Patients after Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria. Cellular Physiology and Biochemistry, 47, 293-301. [Google Scholar] [CrossRef] [PubMed]
[22] Limaye, A.R., Clark, V., Soldevila-Pico, C., et al. (2013) Neutro-phil-Lymphocyte Ratio Predicts Overall and Recurrence-Free Survival after Liver Transplantation for Hepatocellular Car-cinoma. Hepatology Research, 43, 757-764. [Google Scholar] [CrossRef] [PubMed]
[23] 楚伟可, 吴雪, 张鹏, 等. 炎症标志物对早期小肝癌行射频消融术预后的预测价值[J]. 临床肝胆病杂志, 2022, 38(4): 843-850.
[24] 徐馨, 张岚, 易清平, 王艳红, 陈漪. 炎症预后指数对经导管肝动脉化疗栓塞术治疗肝癌疗效的评估价值[J]. 现代肿瘤医学, 2022, 30(17): 3147-3150.
[25] 杨福军, 沈芳, 毕孝杨, 杜运, 刘远洋, 唐艳隆. 术前NLR与TACE治疗肝癌患者预后相关性的Meta分析[J]. 临床放射学杂志, 2022, 41(11): 2051-2058.
[26] 方旭东, 方晓明, 陈达伟, 陈少明, 姚宁, 张人超. NLR和PLR预测经TACE治疗的原发性肝癌患者预后的价值初步分析[J]. 实用肝脏病杂志,2018, 21(3): 431-434.
[27] 张洪海, 孙玉, 生守鹏, 李聪, 孙斌, 张英华, 扈彩霞, 崔雄伟, 李星明, 张永宏, 郑加生. 血小板与淋巴细胞比值、中性粒细胞与淋巴细胞比值对肝细胞癌射频消融术后长期存活患者的预后评估价值[J]. 临床肝胆病杂志, 2019, 35(5): 1014-1020.
[28] 申雪晗, 周江敏, 张志伟, 陈孝平. NLR对TACE联合仑伐替尼及免疫治疗的中晚期肝癌患者预后的预测价值[J]. 肝胆胰外科杂志, 2023, 35(1): 19-24.
[29] 张赟, 王小凡. 肿瘤微环境调控癌症发生发展的研究概述[J]. 中国科学: 生命科学, 2022, 52(9): 1377-1390.
[30] Binnewies, M., Roberts, E.W., Kersten, K., Chan, V., Fearon, D.F., Merad, M., Coussens, L.M., Gabrilovich, D.I., Ostrand-Rosenberg, S., Hedrick, C.C., Vonderheide, R.H., Pittet, M.J., Jain, R.K., Zou, W., Howcroft, T.K., Woodhouse, E.C., Weinberg, R.A. and Krummel, M.F. (2018) Under-standing the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nature Medicine, 24, 541-550. [Google Scholar] [CrossRef] [PubMed]
[31] 李涛, 张侃, 杨文雨, 等. 免疫检查点抑制剂CTLA-4在实体肿瘤治疗中的临床应用[J]. 协和医学杂志, 2023, 14(3): 652-659.
[32] 陆林敏, 张卫平. PD-1/PDL-1及CTLA-4抑制剂治疗原发性肝癌的研究进展[J]. 浙江医学, 2018, 40(13): 1516-1519.
[33] Llovet, J.M., Castet, F., Heikenwal-der, M., Maini, M.K., Mazzaferro, V., Pinato, D.J., Pikarsky, E., Zhu, A.X. and Finn, R.S. (2022) Immunotherapies for Hepatocellular Carcinoma. Nature Reviews Clinical Oncology, 19, 151-172. [Google Scholar] [CrossRef] [PubMed]

为你推荐